DOP2020000060A - Anticuerpo anti-pacap - Google Patents

Anticuerpo anti-pacap

Info

Publication number
DOP2020000060A
DOP2020000060A DO2020000060A DO2020000060A DOP2020000060A DO P2020000060 A DOP2020000060 A DO P2020000060A DO 2020000060 A DO2020000060 A DO 2020000060A DO 2020000060 A DO2020000060 A DO 2020000060A DO P2020000060 A DOP2020000060 A DO P2020000060A
Authority
DO
Dominican Republic
Prior art keywords
antibodies
pacap antibody
migraine
compositions
treatment
Prior art date
Application number
DO2020000060A
Other languages
English (en)
Inventor
Brautigam Beidler Catherine
Parvin Johnson Michael
Natvarlal PATEL Chetankumar
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of DOP2020000060A publication Critical patent/DOP2020000060A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1796—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención ser refiere a anticuerpos contra el péptido activador de la adenilato ciclasa de la pituitaria, composiciones que comprenden tales anticuerpos y métodos para usar tales anticuerpos para el tratamiento del dolor incluyendo cefalea y/o migraña.
DO2020000060A 2017-09-29 2020-03-16 Anticuerpo anti-pacap DOP2020000060A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762565278P 2017-09-29 2017-09-29
PCT/US2018/051898 WO2019067293A1 (en) 2017-09-29 2018-09-20 ANTI-PACAP ANTIBODIES

Publications (1)

Publication Number Publication Date
DOP2020000060A true DOP2020000060A (es) 2020-08-15

Family

ID=63794713

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2020000060A DOP2020000060A (es) 2017-09-29 2020-03-16 Anticuerpo anti-pacap

Country Status (25)

Country Link
US (3) US10519225B2 (es)
EP (1) EP3688035A1 (es)
JP (2) JP6952888B2 (es)
KR (1) KR102453573B1 (es)
CN (1) CN111164105B (es)
AR (1) AR113022A1 (es)
AU (1) AU2018341959B2 (es)
BR (1) BR112020003628A2 (es)
CA (1) CA3077304C (es)
CL (1) CL2020000705A1 (es)
CO (1) CO2020002170A2 (es)
CR (1) CR20200127A (es)
DO (1) DOP2020000060A (es)
EA (1) EA202090563A1 (es)
EC (1) ECSP20020293A (es)
IL (1) IL273529A (es)
JO (1) JOP20200069A1 (es)
MA (1) MA50654A (es)
MX (1) MX2020003563A (es)
NZ (1) NZ762312A (es)
PE (1) PE20201494A1 (es)
SG (1) SG11202002572YA (es)
TW (1) TWI701260B (es)
WO (1) WO2019067293A1 (es)
ZA (1) ZA202001058B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3283517A4 (en) 2015-04-16 2019-03-06 Alder Biopharmaceuticals, Inc. ANTI-PACAP ANTIBODIES AND USES THEREOF
CN109311977B (zh) * 2016-04-15 2022-06-14 H.伦德贝克公司 人源化的抗pacap抗体及其用途
EP4045641A1 (en) 2019-10-15 2022-08-24 Eli Lilly and Company Recombinantly engineered, lipase/esterase-deficient mammalian cell lines
CN117916259A (zh) * 2021-09-30 2024-04-19 江苏恒瑞医药股份有限公司 特异性结合cgrp和pacap的抗原结合分子及其医药用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991014786A1 (en) 1990-03-17 1991-10-03 Takeda Chemical Industries, Ltd. Antibody to pituitary adenylate cyclase activating peptide-pacap, hybridoma and assay for pacap
US6037321A (en) 1995-05-03 2000-03-14 Biostar Inc. Fusion proteins comprising vasoactive intestinal peptide or PACAP
FR2826747B1 (fr) 2001-07-02 2005-02-25 Gemplus Card Int Procede et dispositif de traitement de donnees pour la personnalisation d'une application sur un dispositif communicant portatif, par exemple une carte a puce
WO2004062684A2 (en) 2003-01-16 2004-07-29 D. Collen Research Foundation Vzw Onderwijs En Navorsing Campus Gasthuisberg K.U. Leuven Treatment of thrombocytopenia with inhibitors of pacap
US9939449B2 (en) 2011-02-01 2018-04-10 The University Of Vermont And State Agricultural College Diagnostic and therapeutic methods and products related to anxiety disorders
JP6064861B2 (ja) 2013-03-05 2017-01-25 株式会社デンソー 熱電変換装置の製造方法
WO2014144632A2 (en) * 2013-03-15 2014-09-18 Amgen Inc. Human pac1 antibodies
WO2015023890A1 (en) 2013-08-14 2015-02-19 The Arizona Board Of Regents On Behalf Of The University Of Arizona Glycosylated pacap/vip analogues with enhanced cns penetration for treatment of neurodegenerative diseases
EP3283517A4 (en) * 2015-04-16 2019-03-06 Alder Biopharmaceuticals, Inc. ANTI-PACAP ANTIBODIES AND USES THEREOF
WO2017106578A1 (en) * 2015-12-15 2017-06-22 Amgen Inc. Pacap antibodies and uses thereof
WO2017142961A1 (en) 2016-02-16 2017-08-24 The Arizona Board Of Regents On Behalf Of The University Of Arizona Treatment of traumatic brain injury or stroke

Also Published As

Publication number Publication date
KR20200040881A (ko) 2020-04-20
TW201920280A (zh) 2019-06-01
PE20201494A1 (es) 2020-12-29
SG11202002572YA (en) 2020-04-29
IL273529A (en) 2020-05-31
US20190100579A1 (en) 2019-04-04
CA3077304C (en) 2023-08-01
US20200131256A1 (en) 2020-04-30
CO2020002170A2 (es) 2020-04-01
US10519225B2 (en) 2019-12-31
AU2018341959B2 (en) 2021-11-25
BR112020003628A2 (pt) 2020-09-01
CL2020000705A1 (es) 2020-09-11
CA3077304A1 (en) 2019-04-04
EA202090563A1 (ru) 2020-06-24
KR102453573B1 (ko) 2022-10-12
MX2020003563A (es) 2020-08-03
WO2019067293A1 (en) 2019-04-04
AU2018341959A1 (en) 2020-03-05
CN111164105B (zh) 2023-07-04
US20210171616A1 (en) 2021-06-10
TWI701260B (zh) 2020-08-11
US10954292B2 (en) 2021-03-23
EP3688035A1 (en) 2020-08-05
JOP20200069A1 (ar) 2020-04-28
NZ762312A (en) 2022-11-25
ZA202001058B (en) 2022-06-29
CN111164105A (zh) 2020-05-15
JP7221352B2 (ja) 2023-02-13
JP6952888B2 (ja) 2021-10-27
CR20200127A (es) 2020-04-08
ECSP20020293A (es) 2020-06-30
AR113022A1 (es) 2020-01-15
JP2022000049A (ja) 2022-01-04
MA50654A (fr) 2020-08-05
JP2020535167A (ja) 2020-12-03

Similar Documents

Publication Publication Date Title
ECSP20020293A (es) Anticuerpo anti-pacap
CL2017000410A1 (es) Y-diquetonas para el tratamiento y la prevención de envejecimiento cutáneo y arrugas.
MX2023009483A (es) Anticuerpos monoclonales para usarse para el tratamiento de sinucleinopatia.
CL2019002368A1 (es) Composiciones y métodos para el tratamiento de cáncer.
MX2017010544A (es) Metodos y composiciones para tratar la enfermedad del ojo seco y otros trastornos del ojo.
JOP20170170B1 (ar) صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق
AR095611A1 (es) Anticuerpos que se unen al receptor del polipéptido activador de la adenilato ciclasa pituitaria humana tipo i (hpac1)
BR112017009584A2 (pt) tratamento de retinite pigmentosa com n-acetilcisteína amida
ECSP19057403A (es) Usos terapéuticos de un polvo de insectos
EA201790655A1 (ru) Новые активаторы растворимой гуанилатциклазы и их применение
EA202090457A1 (ru) Комбинированная терапия ласмидитаном и антагонистом cgrp для применения в лечении мигрени
MX2019000428A (es) Agentes y metodos para la prevencion o el tratamiento de infecciones por h. pylori.
CL2019001749A1 (es) Uso de anticuerpos anti-esclerostina en el tratamiento de osteogenesis imperfecta.
CO2021004934A2 (es) Composiciones y métodos para tratar retinitis pigmentosa
MX2020005555A (es) Construcciones inmunogenicas de peptidos de tau.
JOP20190241B1 (ar) مستحضرات رذاذ إبينيفرين
JO3565B1 (ar) الأجسام المضادة لشبيه الأنجيوبوييتين– 4 وطرق استخدامها
CL2021001256A1 (es) Vacunación con el dominio alfa 3 de mica/b para el tratamiento del cáncer (divisional sol 201801470)
EA201791498A1 (ru) Производные глюкагона
DOP2021000215A (es) Tratamiento de la cefalea usando anticuerpo anti-cgrp
EA201992883A1 (ru) АНТИТЕЛА К TrkB
CL2020001846A1 (es) Anticuerpos pac1 y sus usos
EA201690732A1 (ru) Агонисты гуанилатциклазы, используемые для лечения индуцированных опиоидами дисфункций
MX2018015431A (es) Composicion cosmetica anti-signos, uso de la composicion, metodo de tratamiento anti-signos y dispositivo aplicador.
NZ734845A (en) Use of short synthetic peptide for the treatment and/or prophylaxis of dry eye disease